Trim45: A Promising Drug Target and Biomarker for Cancer (G80263)

Target Name: TRIM45

NCBI ID: G80263

TRIM45

Trim45: A Promising Drug Target and Biomarker for Cancer

Cancer is one of the leading causes of morbidity and mortality worldwide, with over 38 million new cases and 18 million cancer-related deaths in 2021, according to the World Health Organization (WHO). The development of new treatments and biomarkers for cancer has become a major focus in the fight against this disease, and TRIM45, a protein expressed in various tissues and cells, is one such promising candidate. In this article, we will explore TRIM45 as a drug target and biomarker for cancer.

The Trim45 Protein

TRIM45, also known as ring finger protein 99, is a 21-kDa protein that is expressed in various tissues and cells, including liver, lung, and breast cells. It is a member of the ring finger gene family, which is known for the presence of a ring-like structure in the protein sequence. TRIM45 is composed of 196 amino acid residues and has a calculated pI of 12.94.

Expression of TRIM45

TRIM45 is expressed in various tissues and cells, including the liver, lung, and breast, and has been shown to play a role in several cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of cell growth, apoptosis, and inflammation.

Drug Targeting and Biomarker Potential

TRIM45 has been identified as a potential drug target for cancer due to its unique structure and its involvement in several cellular processes that are associated with cancer progression. Several studies have shown that TRIM45 can be modulated by various chemical compounds, including inhibitors of tyrosine kinase activity and inhibitors of the DNA damage repair pathway.

One of the most promising strategies for targeting TRIM45 is the use of small molecules, such as inhibitors of tyrosine kinase activity, which can inhibit the signaling pathway responsible for TRIM45 activation. These inhibitors have been shown to inhibit the growth and migration of cancer cells, including human breast and lung adenocarcinoma cells.

Another approach to targeting TRIM45 is the use of antibodies that can specifically recognize and target the protein. The development of monoclonal antibodies (MAbs) that recognize TRIM45 has the potential to provide a highly specific and effective means of targeting cancer cells. Several studies have shown that MAbs against TRIM45 have the potential to selectively bind to TRIM45 and inhibit its signaling pathway.

Biomarker Potential

TRIM45 has also been identified as a potential biomarker for cancer due to its expression in various tissues and its involvement in several cellular processes that are associated with cancer progression. The detection and quantification of TRIM45 expression in cancer cells can be used as a diagnostic tool and as a target for cancer therapies.

Several studies have shown that TRIM45 expression is significantly increased in various types of cancer, including breast, lung, and colorectal cancer. The levels of TRIM45 have also been shown to be associated with the severity of cancer and the response to cancer therapies.

Conclusion

In conclusion, TRIM45 is a promising candidate for cancer treatment due to its unique structure and its involvement in several cellular processes that are associated with cancer progression. The development of inhibitors of TRIM45 signaling pathway and MAbs against TRIM45 have the potential to provide a highly effective means of targeting cancer cells. Further research is needed to fully understand the potential of TRIM45 as a drug target and biomarker for cancer.

Protein Name: Tripartite Motif Containing 45

Functions: May act as a transcriptional repressor in mitogen-activated protein kinase signaling pathway

The "TRIM45 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRIM45 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets